StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note released on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
The company has a market capitalization of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. The firm’s 50-day moving average is $0.14. Nabriva Therapeutics has a 1-year low of $1.22 and a 1-year high of $8.45.
Nabriva Therapeutics Company Profile
Featured Stories
- Five stocks we like better than Nabriva Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- MarketBeat Week in Review – 4/22 – 4/26
- Trading Halts Explained
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Calculate Return on Investment (ROI)
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.